Skip to main content
Alyssa Johnsen, MD, Internal Medicine, Cambridge, MA

Alyssa Johnsen MD

Rheumatology


Physician

Join to View Full Profile
  • 75 Mount Auburn StCambridge, MA 02138

  • Phone+1 617-496-9506

  • Fax+1 617-495-6059

Are you Dr. Johnsen?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Alyssa Johnsen, MD is an internist in Cambridge, Massachusetts.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalFellowship, Rheumatology, 2003 - 2007
  • Mass General Brigham/Massachusetts General Hospital
    Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2003
  • Case Western Reserve University School of Medicine
    Case Western Reserve University School of MedicineClass of 2001

Publications & Presentations

PubMed

Press Mentions

  • Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
    Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024October 28th, 2024
  • New Phase 3 First-in-Class TREMFYA® (Guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)
    New Phase 3 First-in-Class TREMFYA® (Guselkumab) Data Show Durability of Joint Efficacy, Including Low Rates of Structural Damage Progression, and a Demonstrated Safety Profile in Adults with Active Psoriatic Arthritis (PsA)November 1st, 2021
  • New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (Guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
    New Comprehensive Phase 3 Data Show First-in-Class TREMFYA® (Guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two YearsNovember 1st, 2021
  • Join now to see all